[1]
|
van Doorn, P.A., Van den Bergh, P.Y.K., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Attarian, S., et al. (2023) European Academy of Neurology/peripheral Nerve Society Guideline on Diagnosis and Treatment of Guillain-Barré Syndrome. European Journal of Neurology, 30, 3646-3674. https://doi.org/10.1111/ene.16073
|
[2]
|
中国吞咽障碍康复评估与治疗专家共识组. 中国吞咽障碍评估与治疗专家共识(2017年版)第一部分 评估篇[J]. 中华物理医学与康复杂志, 2017, 39(12): 881-892.
|
[3]
|
Eftimov, F., Lucke, I.M., Querol, L.A., Rajabally, Y.A. and Verhamme, C. (2020) Diagnostic Challenges in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Brain, 143, 3214-3224. https://doi.org/10.1093/brain/awaa265
|
[4]
|
Leonhard, S.E., Papri, N., Querol, L., Rinaldi, S., Shahrizaila, N. and Jacobs, B.C. (2024) Guillain-Barré Syndrome. Nature Reviews Disease Primers, 10, Article No. 97. https://doi.org/10.1038/s41572-024-00580-4
|
[5]
|
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B.C. and van Doorn, P.A. (2014) Guillain-Barré Syndrome: Pathogenesis, Diagnosis, Treatment and Prognosis. Nature Reviews Neurology, 10, 469-482. https://doi.org/10.1038/nrneurol.2014.121
|
[6]
|
Rajabally, Y.A. and Uncini, A. (2012) Outcome and Its Predictors in Guillain-Barré Syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 83, 711-718. https://doi.org/10.1136/jnnp-2011-301882
|
[7]
|
Goodfellow, J.A. and Willison, H.J. (2016) Guillain-Barré Syndrome: A Century of Progress. Nature Reviews Neurology, 12, 723-731. https://doi.org/10.1038/nrneurol.2016.172
|
[8]
|
Kesici, S., Tanyıldız, M., Yetimakman, F. and Bayrakci, B. (2019) A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method. Journal of Child Neurology, 34, 277-283. https://doi.org/10.1177/0883073819826225
|
[9]
|
Davidson, A.I., Halstead, S.K., Goodfellow, J.A., Chavada, G., Mallik, A., Overell, J., et al. (2017) Inhibition of Complement in Guillain-Barré Syndrome: The ICA-GBS Study. Journal of the Peripheral Nervous System, 22, 4-12. https://doi.org/10.1111/jns.12194
|
[10]
|
Kuwabara, S., Kusunoki, S., Kuwahara, M., Yamano, Y., Nishida, Y., Ishida, H., et al. (2024) Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Journal of the Peripheral Nervous System, 29, 339-349. https://doi.org/10.1111/jns.12646
|
[11]
|
Sprenger-Svačina, A., Svačina, M.K.R., Gao, T., Zhang, G. and Sheikh, K.A. (2024) Emerging Treatment Landscape for Guillain-Barré Syndrome (GBS): What’s New? Expert Opinion on Investigational Drugs, 33, 881-886. https://doi.org/10.1080/13543784.2024.2377323
|
[12]
|
Zhang, H., Ma, J., Feng, Y., Ma, H., Liu, D., Pang, X., et al. (2024) Efgartigimod in the Treatment of Guillain-Barré Syndrome. Journal of Neurology, 271, 3506-3511. https://doi.org/10.1007/s00415-024-12321-4
|